T. Rowe Price Associates
KLRA

T. Rowe Price Associates’s Kailera Therapeutics KLRA Stock Holding History

T. Rowe Price Associates’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.9M Buy
+3,534,410
New +$77.7M 0.01% 758

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's KLRA Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 3,534,410 shares worth $77.9M. The stake represents 0.01% of the portfolio and ranks #758 among its holdings.

85 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • T. Rowe Price Associates held 3,534,410 shares of Kailera Therapeutics worth $77.9M as of Q2 2026.
  • Kailera Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Kailera Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #758 holding.
  • 85 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.